Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00048971 · ClinicalTrials.gov registry record

Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy

A clinical trial of Colorectal Cancer and Diarrhea, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
308
Enrollment target
20
Study locations

NCT00048971 is a study of Colorectal Cancer and Diarrhea that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 308 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00048971, a study of Colorectal Cancer and Diarrhea, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
308 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Genetic testing may help predict how patients will respond to chemotherapy drugs and may help doctors plan more effective treatment with fewer side effects. PURPOSE: Genetic study to determine how genes affect the severity of diarrhea in patients with stage III colon cancer who are receiving chemotherapy.

Interventions

  • GENETIC mutation analysis
  • GENETIC polymorphic microsatellite marker analysis

Study Locations (20)

California

  • Rebecca and John Moores UCSD Cancer Center - La Jolla
  • Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center - Los Angeles
  • Veterans Affairs Medical Center - San Diego - San Diego
  • UCSF Comprehensive Cancer Center - San Francisco
  • Veterans Affairs Medical Center - San Francisco - San Francisco

Florida

  • Broward General Medical Center - Fort Lauderdale
  • Memorial Regional Hospital Comprehensive Cancer Center - Hollywood
  • CCOP - Mount Sinai Medical Center - Miami Beach
  • Florida Hospital Cancer Institute - Orlando
  • Palm Beach Cancer Institute - West Palm Beach

Illinois

  • MBCCOP - University of Illinois at Chicago - Chicago
  • Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
  • University of Chicago Cancer Research Center - Chicago
  • Louis A. Weiss Memorial Hospital - Chicago
  • West Suburban Center for Cancer Care - River Forest

District of Columbia

  • Lombardi Cancer Center of Georgetown University Medical Center - Washington D.C.
  • Walter Reed Army Medical Center - Washington D.C.
  • Veterans Affairs Medical Center - Washington, DC - Washington D.C.

Alabama

  • Northeast Alabama Regional Medical Center - Anniston

Delaware

  • CCOP - Christiana Care Health Services - Newark

Trial Details

FieldValue
Enrollment Target 308 participants
Start Date 2002-04
Est. Completion 2006-11

What the Registry Record Tells You About NCT00048971

The ClinicalTrials.gov registry entry for NCT00048971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which mutation analysis is the first listed.

NCT00048971 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT00048971 about?

NCT00048971 is a clinical study titled "Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy". RATIONALE: Genetic testing may help predict how patients will respond to chemotherapy drugs and may help doctors plan more effective treatment with fewer side effects. PURPOSE: Genetic study to determine how genes affect the severity of diarrhea in patients with stage III colon cancer who are recei...

What is the current status of trial NCT00048971?

This trial is currently completed. The enrollment target is 308 participants. The study started on 2002-04. Estimated completion is 2006-11.

What conditions does trial NCT00048971 study?

This clinical trial studies the following conditions: Colorectal Cancer, Diarrhea, Neutropenia.

What interventions are being tested in trial NCT00048971?

The interventions under investigation include: mutation analysis (GENETIC), polymorphic microsatellite marker analysis (GENETIC).

Who is sponsoring clinical trial NCT00048971?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00048971 being conducted?

This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.